Editorially independent content, supported with advertising
01.15.26
What types of delays do Stargardt disease patients experience when it comes to diagnosis? And what are the implications for such delays? Alexis Warren, MD, is joined by Jesse Sengillo, MD, and Sruthi Arepalli, MD, to discuss findings from a recent paper quantifying delays in diagnosis and suggesting means by which such delays could be mitigated.
Sponsored by Genentech
01.15.26
New Retina Radio Journal Club w/ VBS: Diagnosis Delays in Stargardt DiseaseAlexis Warren, MD; Jesse Sengillo, MD; and Sruthi Arepalli, MD
Sponsored by Genentech
12.18.25
New Retina Radio Journal Club w/ VBS: Assessing Surgical Competency Among Retina Fellows: Perspectives from Directors and GraduatesNikisha Kothari, MD; Jesse Sengillo, MD; and Nicholas Farber, MD
Editorially Independent Content Supported by Genentech
11.21.25
Endophthalmitis Rates With and Without Antibiotic ProphylaxisSruthi Arepalli, MD; Jesse Sengillo, MD; and Alexis Warren, MD
Editorially Independent Content Support by Genentech
10.10.25
New Retina Radio Journal Club w/ VBS: Time-Driven Cost Analysis of PRP: Dollars, Minutes, and Patient CareNiki Kothari, MD; Jesse Sengillo, MD; and Nicholas Farber, MD
Editorially Independent Content Supported by Genentech
08.13.25
New Retina Radio Journal Club w/ VBS: Obstructive Sleep Apnea and Diabetic RetinopathyLediana Goduni, MD, Alexis Warren, MD, and Joshua Uhr, MD
Editorially independent content sponsored by Genentech and Astellas
07.18.25
Diabetic Retinopathy Severity and Income StatusBen Young, MD; Phoebe Mellen, MD; and Jordan Deaner, MD
Editorially Independent Supported By Genentech and Neurotech.
06.20.25
Photobiomodulation for Age-related Macular DegenerationModerator Barton Blackorby, MD; Hong-Uyen Hua, MD; and Louis Cai, MD
Editorially independent content, supported with advertising by Genentech.
05.16.25
GLP-1s and Risk of Age-Related Ocular DiseaseEditorially independent content, supported with advertising by Genentech and Astellas Pharmaceuticals INC.
03.21.25
Rates of Ocular AEs After Faricimab InjectionMaura Di Nicola, MD; Sruthi Arepalli, MD; and Barton Blackorby, MD
Editorially independent content, supported with advertising by Genentech and Astellas Pharmaceuticals INC.
12.19.24
Switching from Aflibercept to Faricimab in Wet AMD PatientsBen Young, MD, MS; Lediana Goduni, MD; and Joshua Uhr, MD,
Editorially Independent content supported by Apellis.
Show More